BioAegis Therapeutics, Brigham and Women's Hospital deal

The hospital granted BioAegis an exclusive option to license worldwide rights to endogenous human protein plasma gelsolin (pGSN) for therapeutic and diagnostic uses. The option is exercisable at the close of BioAegis' series A financing. BioAegis plans to evaluate the protein, which has completed Phase Ib/IIa testing in ICU patients, as a treatment to maintain local inflammatory responses and prevent systemic inflammation. Phase II testing of the compound is slated for 2012. Terms were not disclosed...